Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4724 ARTÍCULOS , VIENDO DEL 4111 AL 4125

Delivering group speech maintenance therapy via telerehabilitation to people with Parkinson's disease: A pilot study

Quinn R, Park S, Theodoros D, Hill AJ.

Int J Speech Lang Pathol. 2019 Aug;21(4):385-394. doi: 10.1080/17549507.2018.1476918. Epub 2018 Jun 7.

Awareness and current knowledge of Parkinson's disease: a neurodegenerative disorder

Khan AU, Akram M, Daniyal M, Zainab R.

Int J Neurosci. 2019 Jan;129(1):55-93. doi: 10.1080/00207454.2018.1486837. Epub 2018 Nov 22.

Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial

Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, Oryan S, Mafi A, Asemi Z.

Clin Nutr. 2019 Jun;38(3):1031-1035. doi: 10.1016/j.clnu.2018.05.018. Epub 2018 Jun 1.

LRRK2 and mitochondria: Recent advances and current views

Singh A, Zhi L, Zhang H.

Brain Res. 2019 Jan 1;1702:96-104. doi: 10.1016/j.brainres.2018.06.010. Epub 2018 Jun 9.

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease

Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM.

Neuropharmacology. 2019 Mar 15;147:11-27. doi: 10.1016/j.neuropharm.2018.05.035. Epub 2018 Jun 1.

Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects

Vizcarra JA, Situ-Kcomt M, Artusi CA, Duker AP, Lopiano L, Okun MS, Espay AJ, Merola A.

J Neurol. 2019 Feb;266(2):289-297. doi: 10.1007/s00415-018-8936-2. Epub 2018 Jun 16.

Technology-enabled management of communication and swallowing disorders in Parkinson's disease: a systematic scoping review

Theodoros D, Aldridge D, Hill AJ, Russell T.

Int J Lang Commun Disord. 2019 Mar;54(2):170-188. doi: 10.1111/1460-6984.12400. Epub 2018 Jun 19.

Primary tissue for cellular brain repair in Parkinson's disease: Promise, problems and the potential of biomaterials

Moriarty N, Parish CL, Dowd E.

Eur J Neurosci. 2019 Feb;49(4):472-486. doi: 10.1111/ejn.14051. Epub 2018 Jul 10.

Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias

Bordia T, Perez XA.

Eur J Neurosci. 2019 Mar;49(6):859-868. doi: 10.1111/ejn.14048. Epub 2018 Jul 21.

Novel therapies for combating chronic neuropathological sequelae of TBI

Ikonomovic MD, Abrahamson EE, Carlson SW, Graham SH, Dixon CE.

Neuropharmacology. 2019 Feb;145(Pt B):160-176. doi: 10.1016/j.neuropharm.2018.06.021. Epub 2018 Jun 20.

What is the therapeutic mechanism of pedunculopontine nucleus stimulation in Parkinson's disease?

Thevathasan W, Moro E.

Neurobiol Dis. 2019 Aug;128:67-74. doi: 10.1016/j.nbd.2018.06.014. Epub 2018 Jun 19.

GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol

Laun AS, Shrader SH, Brown KJ, Song ZH.

Acta Pharmacol Sin. 2019 Mar;40(3):300-308. doi: 10.1038/s41401-018-0031-9. Epub 2018 Jun 25.

Is Braak staging valid for all types of Parkinson's disease?

Jellinger KA.

J Neural Transm (Vienna). 2019 Apr;126(4):423-431. doi: 10.1007/s00702-018-1898-9. Epub 2018 Jun 25.

Malfunctioning of Chaperone-Mediated Autophagy in Parkinson's Disease: Feats, Constraints, and Flaws of Modulators

Tripathi MK, Rajput C, Mishra S, Rasheed MSU, Singh MP.

Neurotox Res. 2019 Jan;35(1):260-270. doi: 10.1007/s12640-018-9917-z. Epub 2018 Jun 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias